Vera Therapeutics, Inc. (VERA)
34.22
-0.38
(-1.10%)
USD |
NASDAQ |
Aug 28, 16:00
34.22
0.00 (0.00%)
After-Hours: 20:00
Vera Therapeutics Enterprise Value : 2.066B for Aug. 27, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 27, 2026 | 2.066B |
| August 26, 2026 | 2.225B |
| August 25, 2026 | 2.115B |
| August 24, 2026 | 2.002B |
| August 21, 2026 | 1.898B |
| August 20, 2026 | 1.825B |
| August 19, 2026 | 1.898B |
| August 18, 2026 | 1.899B |
| August 17, 2026 | 1.852B |
| August 14, 2026 | 1.852B |
| August 13, 2026 | 1.655B |
| August 12, 2026 | 1.734B |
| August 11, 2026 | 1.756B |
| August 10, 2026 | 1.848B |
| August 07, 2026 | 1.943B |
| August 06, 2026 | 1.880B |
| August 05, 2026 | 1.760B |
| August 04, 2026 | 1.731B |
| August 03, 2026 | 1.895B |
| July 31, 2026 | 1.886B |
| July 30, 2026 | 1.954B |
| July 29, 2026 | 1.915B |
| July 28, 2026 | 1.974B |
| July 27, 2026 | 2.107B |
| July 24, 2026 | 2.127B |
| Date | Value |
|---|---|
| July 23, 2026 | 2.192B |
| July 22, 2026 | 2.170B |
| July 21, 2026 | 2.251B |
| July 20, 2026 | 2.238B |
| July 17, 2026 | 2.346B |
| July 16, 2026 | 2.391B |
| July 15, 2026 | 2.634B |
| July 14, 2026 | 2.680B |
| July 13, 2026 | 2.562B |
| July 10, 2026 | 2.598B |
| July 09, 2026 | 2.631B |
| July 08, 2026 | 2.629B |
| July 07, 2026 | 2.667B |
| July 06, 2026 | 2.464B |
| July 02, 2026 | 2.541B |
| July 01, 2026 | 2.646B |
| June 30, 2026 | 2.664B |
| June 29, 2026 | 2.573B |
| June 26, 2026 | 2.524B |
| June 25, 2026 | 2.383B |
| June 24, 2026 | 2.312B |
| June 23, 2026 | 2.218B |
| June 22, 2026 | 2.235B |
| June 18, 2026 | 1.995B |
| June 17, 2026 | 1.990B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 12.28B |
| Oncolytics Biotech, Inc. | 102.27M |
| Sangamo Therapeutics, Inc. | 55.30M |
| Sarepta Therapeutics, Inc. | 2.538B |
| Anixa Biosciences, Inc. | 107.37M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -109.47M |
| Total Expenses (Quarterly) | 109.47M |
| EPS Diluted (Quarterly) | -1.524 |
| Earnings Yield | -17.15% |
| Normalized Earnings Yield | -17.15 |